{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:58:34Z","timestamp":1780498714782,"version":"3.54.1"},"reference-count":149,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immunotherapy is being tested intensively in clinical trials for prostate cancer; it includes immune checkpoint inhibition, prostate specific antigen (PSA) vaccines and dendritic cell-based strategies. Despite increasing evidence for clinical responses, the consensus of multiple trials is that prostate cancers are poorly responsive to immunotherapy. Prostate cancer has a high degree of pathological and genetic heterogeneity compared to other cancer types, which may account for immunotherapeutic resistance. This hypothesis also implies that select types of prostate tumors may be differentially responsive to immune-based strategies and that the clinical stage, pathological grade and underlying genetic landscape may be important criteria in identifying tumors that respond to immune therapies. One strategy is to target oncogenic driver pathways in combination with immunotherapies with the goal of overcoming tumor immunity and broadening the number of patients achieving a clinical response. In this analysis, we address the hypothesis that driver oncogenic signaling pathways regulate cancer progression, tumor immunity and resistance to current immune therapeutics in prostate cancer. We propose that increased responsiveness may be achieved through the combined use of immunotherapies and inhibitors targeting tumor cell autonomous pathways that contribute towards anti-tumor immunity in patients with prostate cancer.<\/jats:p>","DOI":"10.3390\/ijms18071542","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T03:45:16Z","timestamp":1500349516000},"page":"1542","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Geoffrey","family":"Bryant","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Mulholland","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based psa-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"Provenge (sipuleucel-t) in prostate cancer: The first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4103\/1008-682X.178852","article-title":"Clinical variability and molecular heterogeneity in prostate cancer","volume":"18","author":"Shoag","year":"2016","journal-title":"Asian J. Androl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1038\/onc.2013.409","article-title":"PTEN functions as a melanoma tumor suppressor by promoting host immune response","volume":"33","author":"Dong","year":"2014","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/MCB.00090-14","article-title":"PTEN null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression","volume":"34","author":"Garcia","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1158\/0008-5472.CAN-12-3810","article-title":"Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network","volume":"73","author":"Guo","year":"2013","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","article-title":"Oncogenic braf(v600e) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma","volume":"18","author":"Khalili","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1038\/ncomms5229","article-title":"P38 mapk-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of pten promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to braf inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in braf-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"30386","DOI":"10.1038\/srep30386","article-title":"Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer","volume":"6","author":"Park","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eururo.2014.07.035","article-title":"Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer","volume":"67","author":"Huang","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"22566","DOI":"10.18632\/oncotarget.8124","article-title":"Noninvasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles","volume":"7","author":"Hackenberg","year":"2016","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Siravegna, G., Marsoni, S., Siena, S., and Bardelli, A. (2017). Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol.","DOI":"10.1038\/nrclinonc.2017.14"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Minciacchi, V.R., Zijlstra, A., Rubin, M.A., and Di Vizio, D. (2017). Extracellular vesicles for liquid biopsy in prostate cancer: Where are we and where are we headed?. Prostate Cancer Prostatic Dis.","DOI":"10.1038\/pcan.2017.7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/bjc.2015.332","article-title":"Pten loss in circulating tumour cells correlates with pten loss in fresh tumour tissue from castration-resistant prostate cancer patients","volume":"113","author":"Punnoose","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s13058-014-0445-3","article-title":"TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients","volume":"16","author":"Fernandez","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.6004\/jnccn.2014.0072","article-title":"Prostate cancer, version 2.2014","volume":"12","author":"Mohler","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.coph.2008.07.005","article-title":"Targeting the androgen receptor pathway in prostate cancer","volume":"8","author":"Chen","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.7150\/ijbs.8671","article-title":"Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer","volume":"10","author":"Kahn","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Trotman, L.C., Niki, M., Dotan, Z.A., Koutcher, J.A., Di Cristofano, A., Xiao, A., Khoo, A.S., Roy-Burman, P., Greenberg, N.M., and Van Dyke, T. (2003). PTEN dose dictates cancer progression in the prostate. PLoS Biol., 1.","DOI":"10.1371\/journal.pbio.0000059"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrurol.2014.243","article-title":"Emerging mechanisms of enzalutamide resistance in prostate cancer","volume":"11","author":"Claessens","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00262-009-0782-8","article-title":"Immunologic and prognostic factors associated with overall survival employing a poxviral-based psa vaccine in metastatic castrate-resistant prostate cancer","volume":"59","author":"Gulley","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-t in the immunotherapy for prostate adenocarcinoma treatment (impact) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Williams, C.B., Yeh, E.S., and Soloff, A.C. (2016). Tumor-associated macrophages: Unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer, 2.","DOI":"10.1038\/npjbcancer.2015.25"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1055-9965.EPI-13-1126","article-title":"Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial","volume":"23","author":"Gurel","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fphar.2016.00376","article-title":"Systemic immune-inflammation index predicts the clinical outcome in patients with mcrpc treated with abiraterone","volume":"7","author":"Lolli","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/1078-0432.CCR-14-2235","article-title":"Aspirin, nsaids, and risk of prostate cancer: Results from the reduce study","volume":"21","author":"Vidal","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1172\/JCI28828","article-title":"Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells","volume":"116","author":"Gallina","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"ref_46","first-page":"523","article-title":"Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy","volume":"3","author":"Gollapudi","year":"2013","journal-title":"Am. J. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15651","DOI":"10.1038\/srep15651","article-title":"Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions","volume":"5","author":"Lundholm","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/ijc.22900","article-title":"Modulating metastasis by a lymphangiogenic switch in prostate cancer","volume":"121","author":"Brakenhielm","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1158\/1078-0432.CCR-06-1558","article-title":"Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy","volume":"12","author":"Li","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fonc.2015.00202","article-title":"Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: An overview of rationale, preclinical evidence, and initial clinical data","volume":"5","author":"Ott","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2015.65.3154","article-title":"A randomized phase ii trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy","volume":"34","author":"McKay","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_53","unstructured":"Docetaxel with or without low-dose, short course sunitinib in refractory solid tumors, NCT01803503."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fonc.2015.00128","article-title":"Immune infiltration and prostate cancer","volume":"5","author":"Strasner","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-07-0842","article-title":"CD8+ FOXP3+ regulatory t cells mediate immunosuppression in prostate cancer","volume":"13","author":"Kiniwa","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.prnil.2015.06.002","article-title":"Association between tumor-associated macrophages and microvessel density on prostate cancer progression","volume":"3","author":"Yuri","year":"2015","journal-title":"Prostate Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3892\/ol.2015.3400","article-title":"Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma","volume":"10","author":"Hu","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1038\/cddis.2013.270","article-title":"Anti-androgen receptor asc-j9 versus anti-androgens MDV3100 (enzalutamide) or casodex (bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling","volume":"4","author":"Lin","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/0008-5472.CAN-14-0992","article-title":"CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy","volume":"75","author":"Escamilla","year":"2015","journal-title":"Cancer Res."},{"key":"ref_60","first-page":"3181","article-title":"Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer","volume":"7","author":"Chi","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent mdsc infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1096\/fj.04-3213fje","article-title":"p53 Is a suppressor of inflammatory response in mice","volume":"19","author":"Komarova","year":"2005","journal-title":"FASEB J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11409","DOI":"10.1007\/s13277-014-2464-1","article-title":"Analysis of TIM-3 as a therapeutic target in prostate cancer","volume":"35","author":"Piao","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Cortez, M.A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H.J., Ye, Y., Araujo, L., Carbone, D.P., Shilo, K., and Giri, D.K. (2016). Pdl1 regulation by p53 via miR-34. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djv303"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"Ras\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between mek and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of mapk in melanoma cells resistant to braf inhibition promotes PD-L1 expression that is reversible by mek and PI3K inhibition","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of mapk and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.molimm.2011.05.004","article-title":"Activation of mitogen activated protein kinase-erk kinase (MEK) increases t cell immunoglobulin mucin domain-3 (TIM-3) transcription in human t lymphocytes and a human mast cell line","volume":"48","author":"Yoon","year":"2011","journal-title":"Mol. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/pcan.2015.39","article-title":"Paucity of pd-l1 expression in prostate cancer: Innate and adaptive immune resistance","volume":"18","author":"Martin","year":"2015","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on t-cell infiltration and pd-l1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Fong, L., Carroll, P., Weinberg, V., Chan, S., Lewis, J., Corman, J., Amling, C.L., Stephenson, R.A., Simko, J., and Sheikh, N.A. (2014). Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl. Cancer Inst., 106.","DOI":"10.1093\/jnci\/dju268"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2326-6066.CIR-13-0108","article-title":"Immune impact induced by prostvac (PSA-tricom), a therapeutic vaccine for prostate cancer","volume":"2","author":"Gulley","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1600-0463.2010.02604.x","article-title":"Distribution of foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue","volume":"118","author":"Valdman","year":"2010","journal-title":"APMIS"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ejca.2012.11.035","article-title":"High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer","volume":"49","author":"Flammiger","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4161\/onci.1.2.18480","article-title":"Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer","volume":"1","author":"Zhao","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/j.1464-410X.2010.09804.x","article-title":"Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer","volume":"107","author":"Nonomura","year":"2011","journal-title":"BJU Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jim.2009.06.004","article-title":"Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients","volume":"348","author":"Gannon","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1158\/0008-5472.CAN-11-2499","article-title":"Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory t cells","volume":"72","author":"Tang","year":"2012","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-07-5164","article-title":"Phenotypic analysis of prostate-infiltrating lymphocytes reveals Th17 and treg skewing","volume":"14","author":"Sfanos","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","article-title":"TGF-\u03b2 and immune cells: An important regulatory axis in the tumor microenvironment and progression","volume":"31","author":"Yang","year":"2010","journal-title":"Trends Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1158\/1078-0432.CCR-16-1780","article-title":"Sequencing of sipuleucel-t and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: A phase ii randomized trial","volume":"23","author":"Antonarakis","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ajpath.2012.07.008","article-title":"Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: Lessons from conditional ar knockout mice","volume":"181","author":"Lai","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"333ra347","DOI":"10.1126\/scitranslmed.aad5659","article-title":"Androgen receptor antagonists compromise t cell response against prostate cancer leading to early tumor relapse","volume":"8","author":"Pu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"397.e9","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00007890-199808150-00015","article-title":"Glucocorticoids inhibit activation-dependent expression of costimulatory molecule B7\u20131 in human monocytes","volume":"66","author":"Girndt","year":"1998","journal-title":"Transplantation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molmed.2007.02.001","article-title":"Glucocorticoid signaling: A nongenomic mechanism for T-cell immunosuppression","volume":"13","author":"Lowenberg","year":"2007","journal-title":"Trends Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s000180050403","article-title":"Dexamethasone enhances CTLA-4 expression during t cell activation","volume":"55","author":"Xia","year":"1999","journal-title":"Cell Mol. Life Sci."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Xing, K., Gu, B., Zhang, P., and Wu, X. (2015). Dexamethasone enhances programmed cell death 1 (pd-1) expression during t cell activation: An insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunol., 16.","DOI":"10.1186\/s12865-015-0103-2"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Li, J., Alyamani, M., Zhang, A., Chang, K.H., Berk, M., Li, Z., Zhu, Z., Petro, M., Magi-Galluzzi, C., and Taplin, M.E. (2017). Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. eLife, 6.","DOI":"10.7554\/eLife.20183"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1210\/jc.2002-020970","article-title":"11\u03b2-hydroxysteroid dehydrogenase types 1 and 2: An important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids","volume":"87","author":"Diederich","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/1097-0142(20000915)89:6<1380::AID-CNCR23>3.0.CO;2-R","article-title":"Docetaxel-induced lymphopenia in patients with solid tumors: A prospective phenotypic analysis","volume":"89","author":"Kotsakis","year":"2000","journal-title":"Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"286170","DOI":"10.1155\/2014\/286170","article-title":"Selective depletion of regulatory t cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer","volume":"2014","author":"Li","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances t-cell responses and antitumor activity: Effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-1016-03","article-title":"Cellular immunity in breast cancer patients completing taxane treatment","volume":"10","author":"Carson","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2174\/1381612023394089","article-title":"Immune modulation by ionizing radiation and its implications for cancer immunotherapy","volume":"8","author":"Friedman","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Cho, Y., Chang, J.S., Rha, K.H., Hong, S.J., Choi, Y.D., Ham, W.S., Kim, J.W., and Cho, J. (2016). Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147191"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/pros.20794","article-title":"Radiotherapy augments the immune response to prostate cancer in a time-dependent manner","volume":"68","author":"Harris","year":"2008","journal-title":"Prostate"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase i\/ii study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184\u2013043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.juro.2007.03.003","article-title":"Guideline for the management of clinically localized prostate cancer: 2007 update","volume":"177","author":"Thompson","year":"2007","journal-title":"J. Urol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/13543780902997928","article-title":"Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","article-title":"Prostate-specific deletion of the murine pten tumor suppressor gene leads to metastatic prostate cancer","volume":"4","author":"Wang","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_113","unstructured":"Genentech, Inc. Study of ipatasertib or GDC-0980 with abiraterone acetate versus coralie in participants with castration-resistant prostate cancer previously treated with docetaxel chemotherapy, NCT02215096."},{"key":"ref_114","unstructured":"GlaxoSmithKline. Dose-finding study of GSK2636771 when administered in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer, NCT02215096, 2018."},{"key":"ref_115","unstructured":"AstraZeneca. AZD8186 first time in patient ascending dose study, NCT01884285, 2017."},{"key":"ref_116","unstructured":"Institute of Cancer Research, UK; Royal Marsden, NHS Foundation Trust. A study of enzalutamide in combination with AZD5363 in patients with MCRPC, NCT02525068, 2018."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrc2402","article-title":"Recurrent gene fusions in prostate cancer","volume":"8","author":"Tomlins","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/sj.bjc.6604054","article-title":"Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer","volume":"97","author":"Nam","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"10242","DOI":"10.1158\/0008-5472.CAN-06-1986","article-title":"TMPRSS2 fusions with oncogenic ets factors in prostate cancer involve unbalanced genomic rearrangements and are associated with hdac1 and epigenetic reprogramming","volume":"66","author":"Iljin","year":"2006","journal-title":"Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/onc.2015.109","article-title":"The oncogene erg: A key factor in prostate cancer","volume":"35","author":"Adamo","year":"2016","journal-title":"Oncogene"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-13-2543","article-title":"NF-\u03baB gene signature predicts prostate cancer progression","volume":"74","author":"Jin","year":"2014","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.celrep.2014.08.049","article-title":"NF-\u03baB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells","volume":"9","author":"Wang","year":"2014","journal-title":"Cell Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1158\/0008-5472.CAN-13-0882","article-title":"ERG is a critical regulator of WNT\/LEF1 signaling in prostate cancer","volume":"73","author":"Wu","year":"2013","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fimmu.2016.00460","article-title":"Modulation of inflammatory responses by WNT\/\u03b2-catenin signaling in dendritic cells: A novel immunotherapy target for autoimmunity and cancer","volume":"7","author":"Suryawanshi","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_126","unstructured":"Novartis, Pharmaceuticals. A study of LGK974 in patients with malignancies dependent on wnt ligands, NCT01351103, 2018."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrurol.2015.182","article-title":"Prostate cancer: Intrapatient heterogeneity in prostate cancer","volume":"12","author":"Beltran","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40425-015-0053-5","article-title":"New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy","volume":"3","author":"Guo","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri.2016.99","article-title":"Emerging roles of p53 and other tumour-suppressor genes in immune regulation","volume":"16","author":"Mandinova","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e1794","DOI":"10.1038\/cddis.2015.143","article-title":"APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells","volume":"6","author":"Mohell","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 AND MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Boysen, G., Barbieri, C.E., Prandi, D., Blattner, M., Chae, S.S., Dahija, A., Nataraj, S., Huang, D., Marotz, C., and Xu, L. (2015). SPOP mutation leads to genomic instability in prostate cancer. eLife, 4.","DOI":"10.7554\/eLife.09207"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 blockade synergizes therapeutically with parp inhibition in BRCA1-deficient ovarian cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_136","unstructured":"AstraZeneca. Study of olaparib (lynparza\u2122) versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (profound study), NCT02987543, 2020."},{"key":"ref_137","unstructured":"Clovis Oncology, Inc.; Foundation, Medicine. A study of rucaparib in patients with metastatic castration-resistant prostate cancer and homologous recombination gene deficiency, NCT02952534, 2019."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.K., Hsu, J.M., Hsu, J.L., Yu, W.H., Du, Y., and Lee, H.H. (2017). Parp inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant kras in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/bjc.2011.163","article-title":"Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer","volume":"104","author":"Mukherjee","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","article-title":"Pten loss and RAS\/MAPK activation cooperate to promote emt and metastasis initiated from prostate cancer stem\/progenitor cells","volume":"72","author":"Mulholland","year":"2012","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood-2005-06-2486","article-title":"Tumor evasion of the immune system: Inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma","volume":"107","author":"Wang","year":"2006","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes t cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"ref_144","unstructured":"Effector, Therapeutics. A dose escalation and cohort-expansion study of oral EFT508 in subjects with advanced solid tumors, NCT02605083, 2017."},{"key":"ref_145","unstructured":"Jonsson Comprehensive Cancer Center; National Cancer, Institute. Trametinib in treating patients with progressive metastatic hormone-resistant prostate cancer, NCT02881242, 2018."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","article-title":"Total therapy 3 for multiple myeloma: Prognostic implications of cumulative dosing and premature discontinuation of vtd maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy","volume":"116","author":"Szymonifka","year":"2010","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-CAS9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/7\/1542\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:42:56Z","timestamp":1760208176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/7\/1542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":149,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["ijms18071542"],"URL":"https:\/\/doi.org\/10.3390\/ijms18071542","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]}}}